Back to search

Article

Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer

2023-05-06

Abstract excerpt

<h4>Background: </h4> Men with incurable castration resistant prostate cancer (CRPC) are typically treated with taxanes; however, drug resistance rapidly develops. Thus, overcoming taxane resistant PC is a major clinical need. We previously identified a seven gene network in aggressive CRPC, which includes the mitotic serine threonine kinase BUB1 , a major regulator of the spindle assembly checkpoint (SAC). Alter...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
453eb309-b014-521a-88f3-4fce6b6095a3
DOI
10.1101/2023.05.05.539598
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancerDOI 10.1101/2023.05.05.539598
Select a neighboring publication to make it the new centre.